Innovative Health Technologies Limited v. Crawford

District Court, D. Arizona·Decided July 29, 2020·No. 2:18-cv-03372·Unknown

Opinion

WO

Innovative Health Technologies, No. CV-18-03372-PHX-ROS

Plaintiff, ORDER AND FINAL JUDGMENT

v.

Rustam Urmeev,

Defendant. Plaintiff Innovative Health Technologies (“IHT”) seeks default judgment against Defendant Rustam Urmeev. (Doc. 72). While IHT is entitled to default judgment, it is not entitled to the full amount of monetary damages it seeks nor is it entitled to the full scope of injunctive relief it requests. Thus, the motion for default judgment will be granted in part. “The general rule of law is that upon default the factual allegations of the complaint, except those relating to the amount of damages, will be taken as true.” TeleVideo Sys., Inc. v. Heidenthal, 826 F.2d 915, 917-18 (9th Cir. 1987). The second amended complaint sets forth the following facts. (Doc. 38). “IHT is a market leader in innovative medical devices for the consuming public.” (Doc. 38 at 5). After years of research, IHT developed its “AVEOtsd apparatus” to treat snoring and sleep apnea. That apparatus is “a one-piece tongue stabilizing device formed of a resiliently flexible material and comprises a body having a hollow interior within which the end of a user’s tongue fits and is held by negative pressure.” (Doc. 38 at 5). IHT obtained a patent covering that apparatus (“the ‘506 Patent”) and began selling the apparatus throughout the United States and internationally. IHT advertises the apparatus on a nationwide and worldwide basis. Sometime prior to 2017, Urmeev and his partners established a business known as “ZenSleep.” As early as January 2017, Urmeev and his partners manufactured and sold a variety of “snoring solutions” through ZenSleep. One of those “snoring solutions” was an apparatus known as the “ZenGuard.” (Doc. 38 at 7). The ZenGuard reads on all the claims of IHT’s patent. In fact, it appears to be a simple copy of the AVEOtsd apparatus. In marketing the ZenGuard, Urmeev claimed he invented the ZenGuard and that there was “nothing like [it] on the market.” (Doc. 38 at 7). And on the ZenSleep website, Urmeev claimed ZenSleep was an “FDA Approved Facility” and that the facility had been featured in publications such as Forbes and WebMD. (Doc. 38 at 8). All of these representations by Urmeev were false. In addition, the ZenSleep website contained an instructional video allegedly explaining how to use the ZenGuard. That video, however, “actually shows IHT’s AVEOtsd devoice, and not the infringing ZenGuard product.” (Doc. 38 at 8-9). Using a video showing IHT’s product to advertise the ZenGuard establishes Urmeev was aware of IHT’s product and was consciously attempting to capitalize on that product’s success. IHT learned of Urmeev’s sale of the infringing apparatus and repeatedly informed him that he was infringing the ‘506 Patent and engaged in false advertising. Urmeev ignored those communications and continued to sell the infringing apparatus. Thus, Urmeev had “actual knowledge and notice of IHT’s ownership of the ‘506 Patent” but continued his infringing activities. (Doc. 38 at 10). In October 2018, IHT filed the present suit against Urmeev’s business partners. (Doc. 1). Later, IHT added Urmeev as a defendant. (Doc. 38). IHT alleged two claims against Urmeev and his partners: 1) patent infringement; and 2) false advertising/unfair competition under federal law. (Doc. 38 at 10-11). IHT alleged Urmeev’s conduct was “willful, wanton, and deliberate” such that any damages for patent infringement or false advertising should be trebled. (Doc. 38 at 13-14). Urmeev avoided service but was eventually served through mail, email, publication, and his attorneys for other matters. (Doc. 60). Urmeev never appeared and his default was entered.1 (Doc. 73). As for his partners, they were served and they filed an answer. The partners produced discovery indicating Urmeev and his partners had total profits in 2017 of $1,558,568 and total profits in 2018 of $406,735.89. No documentation was produced regarding 2016 or 2019. Thus, Urmeev’s total profits during the relevant time of 2016 through 2019 were $1,965,303.89. That figure is established by documentation produced by Urmeev’s own business partners and there is no reason to doubt the figure’s accuracy. IHT and Urmeev’s business partners eventually settled, leaving Urmeev the sole defendant.2 There are seven factors the Court must consider when determining whether to enter default judgment: “(1) the possibility of prejudice to the plaintiff, (2) the merits of plaintiff’s substantive claim, (3) the sufficiency of the complaint, (4) the sum of money at stake in the action; (5) the possibility of a dispute concerning material facts; (6) whether the default was due to excusable neglect, and (7) the strong policy underlying the Federal Rules of Civil Procedure favoring decisions on the merits.” Eitel v. McCool, 782 F.2d 1470, 1471-72 (9th Cir. 1986). These factors support entry of default judgment. First, given Urmeev’s refusal to appear or participate in this litigation, IHT has no other means of obtaining redress for Urmeev’s behavior. Thus, absent a default judgment IHT will suffer severe prejudice. The second and third factors can be analyzed together as they involve the adequacy of the complaint and the strength of IHT’s claims. The second amended complaint

Free access — add to your briefcase to read the full text and ask questions with AI

Innovative Health Technologies Limited v. Crawford, (D. Ariz. 2020).

Innovative Health Technologies Limited v. Crawford (Innovative Health Technologies Limited v. Crawford) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related